Online citations, reference lists, and bibliographies.
← Back to Search

Randomised Controlled Trial To Compare The Diagnostic Yield Of Positron Emission Tomography CT (PET-CT) TARGETed Pleural Biopsy Versus CT-guided Pleural Biopsy In Suspected Pleural Malignancy (TARGET Trial)

D. de Fonseka, Wendy A Underwood, L. Stadon, N. Rahman, A. Edey, C. Rogers, N. Maskell
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Introduction Pleural malignancy, particularly malignant pleural mesothelioma (MPM) is increasing in incidence due to the long latency period from exposure to asbestos to development of the disease. MPM can be challenging to diagnose. For patients presenting without a pleural effusion, CT-guided biopsy remains the primary choice of biopsy, but the diagnostic sensitivity of this investigation is 70%–75%. Therefore, a proportion of patients will go on to require further biopsies. If the first biopsy is non-diagnostic, the chances of further non-diagnostic biopsies are high in MPM. Methods Target is a multicentre randomised controlled trial, aiming to recruit 78 patients over a 30-month period, from 10 centres in the UK. Patients will be randomised to either the standard arm which is a second CT-guided biopsy, or the interventional arm, a positron emission tomography-CT scan followed by a targeted CT-guided biopsy. Patients will be followed up for 12 months (patients recruited in the last 6 months of recruitment will have 6 months of follow-up). MPM biomarker mesothelin will be checked at baseline, 6 month and 12 month follow-up appointments where patients are able to attend these appointments. Ethics and dissemination Ethical approval for this trial was granted by the South West—Exeter research and ethics committee (reference number 15/SW/0156). Results of the trial will be published in a peer-reviewed journal and presented at an international conference. Trial registration number ISRCTN14024829; Pre-results.
This paper references
Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.
R. Stephens (2015)
Incidence of malignant mesothelioma in Germany 2009–2013
Martin Lehnert (2016)
Biomarkers in mesothelioma
D. Arnold (2018)
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
J. M. Porcel (2015)
Serum Endostatin Concentrations Are Higher in Men with Symptoms of Intermittent Claudication
J. Golledge (2014)
MRI and CT in the differential diagnosis of pleural disease.
J. Hierholzer (2000)
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
S. Armato (2016)
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
P. Zucali (2017)
Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
G. Treglia (2014)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar